Phase I study of the antineovascularization drug CM101

Clinical Cancer Research

Volumn 3, Issue 3, 1997, Pages 365-372

  DeVore, Russell F ^a   Hellerqvist, Carl G ^a   Wakefield, Gail B ^a   Wamil, Barbara D ^a   Thurman, Gary B ^a   Minton, Patricia A ^a   Sundell, Håkan W ^a   Yan, He Ping ^b   Carter, Clint E ^b   Wang, Yue Fen ^a   York, Gerald E ^a   Zhang, Ming Hua ^a   Johnson, David H ^a  

^a VANDERBILT UNIVERSITY   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL POLYSACCHARIDE; CM 101; CYTOKINE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; COUGHING; DYSPNEA; FEMALE; FEVER; FLUSHING; HEADACHE; HEART ARRHYTHMIA; INTRAVENOUS DRUG ADMINISTRATION; MALE; MYALGIA; NAUSEA; PAIN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; POLYSACCHARIDES, BACTERIAL; SKIN TESTS;

EID: 0030887267     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Plate, K. H., Breier, G., and Risau, W. Molecular mechanisms of developmental and tumor angiogenesis. Brain Pathol., 4: 207-218, 1994.
2. Maragoudakis, M. E., Gullino, P. M, and Lelkes, P. I, (eds.). Angiogenesis; molecular biology, clinical aspects, Vol. 263, pp. 1-372. New York: Plenum Press, 1994.
3. Folkman, J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med., 255: 1182-1186, 1971.
4. Fidler, I. J. Critical factors in the biology of human cancer metastasis. Cancer Res., 50: 6130-6138, 1990.
5. Fidler, I. J., and Ellis, L. M. The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell, 79: 185-188, 1994.
6. Hellerqvist, C. G., Rojas, J., Green, R. S., Sell, S., Sundell, H., and Stahlman, M. T. Studies on group B β-hemolytic Streptococcus. I. Isolation and partial characterization of an extracellular toxin. Pediatr. Res., 15: 892-898, 1981.
7. Rojas, J., Green, R. S., Hellerqvist, C. G., Olegard, R., Brigham, K. L., and Stahlman, M. T. Studies on group B β-hemolytic Streptococcus. II. Effects on pulmonary hemo-dynamics and vascular permeability in unanesthetized sheep. Pediatr. Res., 15: 899-904, 1981.
8. Rojas, J., Larrson, L. E., Hellerqvist, C. G., Brigham, K. L., Gray, M. E., and Stahlman, M. T. Pulmonary hemodynamic and ultrastructural changes associated with group B streptococcal toxemia in adult sheep and newborn lambs. Pediatr. Res., 17: 1002-1008, 1983.
9. Weisman, L. E., Stoll, B. J., Cruess, D. F., Hall, R. T., Merenstein, G. B., Hemming, V. G., and Fischer, G. W. Early-onset group B streptococcal sepsis: a current assessment. J, Pediatr., 121: 428-433, 1992.
10. Russell, B. A., Pappas, R. S., Brandt, J. M., Sundell, H. W., and Hellerqvist, C. G. Immunological and histochemical studies on the pathophysiology of group B streptococcal toxin manifested in earlyonset disease. Glycoconj. J., 6: 399, 1988.
11. Hellerqvist, C. G., Thurman, G. B., Page, D. L., Wang, Y-F., Russell, B. A., Montgomery, C. A., and Sundell, H. W. Anti-tumor effects of GBS toxin; a polysaccharide exotoxin from group B β-hemolytic Streptococcus. Cancer Res. Clin. Oncol., 120: 63-70, 1993.
12. Thurman, G. B., Russell, B. A., York, G. E., Wang, Y-F., Page, D. L., Sundell, H. W., and Hellerqvist, C. G. Effects of GBS toxin on long-term survival of mice bearing transplanted Madison lung tumors. Cancer Res. Clin. Oncol., 720: 479-484, 1994.
13. Sandberg, K., Edberg, K. E., Fish, W., Parker, R. A., Hellerqvist, C. G., and Sundell, H. Thromboxane receptor blockage fSQ 29548) in group B streptococcal (GBS) toxin challenge in young lambs. Pediatr. Res., 35: 571-579, 1994.
14. Gearing, A. J. H., and Newman, W. Circulating adhesion molecules in disease. Immunol. Today, 14: 506-512, 1993.
15. Kasama, T., Stricter, R. M., Standiford, T. J., Burdick, M. D., and Kunkel, S. L. Expression and regulation of human neutrophil-derived macrophage inflammatory protein 1 alpha. J. Exp. Med., 775: 63-72, 1993.
16. Taub, D. D., Conlon, K., Lloyd, A. R., Oppenheim, J. J., and Kelvin, D. J. Preferential migration of activated CD4+ and CD8 + T cells in response to MIP-la and MIP-lβ. Science (Washington DC), 260: 355-358, 1993.
17. Beutler, B., and Cerami, A. Cachectin/tumor necrosis factor: an endogenous mediator of shock and inflammation. Immunol. Res., 5: 281, 1986.
18. Cassatella, M. A. The production of cytokines by polymorphonuclear neutrophils. Immunol. Today, 16: 21-26, 1995.
19. Baumann, H., and Gauldie, J. The acute phase response. Immunol. Today, 15: 74-80, 1994.
20. Gomez, J. J., Martin, M. C., Sauri, R., Segura, R. M., Esteban, F., Ruiz, J. C., Nuvials, X., Boveda, J. L., Peracaula, R., and Salgado, A. Interleukin-10 and monocyte/macrophage-induced inflammatory response in septic shock. J. Infect. Dis., 171: 472-475, 1995.
21. Wamil, B. D., Thurman, G. B., Sundell, H., DeVore, R. F., Wakefield, G., Johnson, D. H., Wang, Y-F., and Hellerqvist, C. G. Soluble E-selectin in cancer patients as a marker of the therapeutic efficacy of CM 101, a tumor inhibiting anti-neovascularization agent, evaluated in phase I clinical trial. J. Cancer Res. Clin. Oncol., in press, 1997.